BR112014019116A8 - Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo - Google Patents
Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpoInfo
- Publication number
- BR112014019116A8 BR112014019116A8 BR112014019116A BR112014019116A BR112014019116A8 BR 112014019116 A8 BR112014019116 A8 BR 112014019116A8 BR 112014019116 A BR112014019116 A BR 112014019116A BR 112014019116 A BR112014019116 A BR 112014019116A BR 112014019116 A8 BR112014019116 A8 BR 112014019116A8
- Authority
- BR
- Brazil
- Prior art keywords
- bispecific
- antibody molecules
- cells
- antibody
- kit
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000013598 vector Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
KIT, MOLÉCULAS DE ANTICORPO, COMPOSIÇÃO FARMACÊUTICA, MÉTODOS DE TRATAMENTO, USOS, VETOR, CÉLULA HOSPEDEIRA E MÉTODO DE PRODUÇÃO DE UMA MOLÉCULA DE ANTICORPO. A presente invenção refere-se a uma molécula de anticorpo (monoclonal) biespecífico com um primeiro domínio de ligação que se liga a um antígeno em células T CD8+ que não ocorre naturalmente em e/ou sobre células T CD8+, e um segundo domínio de ligação que se liga a um antígeno tumor-específico de ocorrência natural na superfície de uma célula tumoral. As moléculas de anticorpo biespecífico (monoclonal) são particularmente úteis em combinação com as células T CD8+ transduzidas compreendendo um antígeno que não ocorre naturalmente em e/ou sobre células T CD8+ e/ou com um receptor de célula T. A invenção também provê o uso das referidas moléculas de anticorpo (biespecífico) como um medicamento, as moléculas de anticorpo (biespecífico) para uso em um método para o tratamento de doenças específicas, bem como uma composição farmacêutica/medicamento compreendendo as referidas moléculas de anticorpo (biespecífico), em que as referidas moléculas de anticorpo (biespecífico) devem ser administradas em combinação com células T CD8+ transduzidas compreendendo um antígeno que não ocorre naturalmente em e/ou sobre células T CD8+ e/ou um receptor de célula T em um regime de tratamento específico. Outros aspectos da invenção são sequências de ácidos nucleicos codificantes das referidas moléculas de anticorpo biespecífico (monoclonal), vetores, células hospedeiras, métodos para a produção da molécula de anticorpo (biespecífico), bem como um kit que compreende a molécula de anticorpo (biespecífico).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12153786.4 | 2012-02-03 | ||
EP12153786 | 2012-02-03 | ||
PCT/EP2013/051351 WO2013113615A1 (en) | 2012-02-03 | 2013-01-24 | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014019116A8 true BR112014019116A8 (pt) | 2017-07-11 |
BR112014019116A2 BR112014019116A2 (pt) | 2018-10-09 |
BR112014019116B1 BR112014019116B1 (pt) | 2024-01-23 |
Family
ID=47747562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014019116-6A BR112014019116B1 (pt) | 2012-02-03 | 2013-01-24 | Kit, moléculas de anticorpo e uso de uma molécula de anticorpo |
Country Status (11)
Country | Link |
---|---|
US (2) | US10633451B2 (pt) |
EP (1) | EP2809682B1 (pt) |
JP (2) | JP6363021B2 (pt) |
KR (1) | KR102091297B1 (pt) |
CN (1) | CN104379601B (pt) |
BR (1) | BR112014019116B1 (pt) |
CA (1) | CA2861031C (pt) |
HK (1) | HK1207094A1 (pt) |
MX (1) | MX366965B (pt) |
RU (1) | RU2693264C2 (pt) |
WO (1) | WO2013113615A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
US10633451B2 (en) * | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
RU2015117393A (ru) | 2012-10-08 | 2016-12-10 | Роше Гликарт Аг | Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
AU2015292406B2 (en) | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
TW202130662A (zh) | 2015-01-23 | 2021-08-16 | 法商賽諾菲公司 | 特異性結合cd3及/或cd123之抗—cd3抗體,抗—cd123抗體及雙特異性抗體 |
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
KR102537102B1 (ko) | 2015-05-29 | 2023-05-25 | 엠피베나 테라퓨틱스, 인크. | 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법 |
IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
CN104892765B (zh) * | 2015-06-29 | 2018-04-10 | 深圳市国创纳米抗体技术有限公司 | 一种抗CD3抗原和Her‑2抗原的双特异性抗体 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
MX2018003822A (es) | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. |
CN105384826A (zh) * | 2015-11-19 | 2016-03-09 | 广州熙帝生物科技有限公司 | 表达嵌合抗原受体的脐血有核细胞及其应用 |
WO2017123627A1 (en) * | 2016-01-11 | 2017-07-20 | Stc Biologics, Inc. | Bispecific targeting agents and methods for their preparation |
WO2017219974A1 (zh) * | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
MX2018015414A (es) * | 2016-06-30 | 2019-08-01 | Hoffmann La Roche | Terapia de célula t adoptiva mejorada. |
CN110177571B (zh) * | 2016-11-18 | 2024-05-24 | 加利福尼亚大学董事会 | 工程化抗体及其用途 |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
CR20190431A (es) * | 2017-03-27 | 2019-11-01 | Hoffmann La Roche | Formatos mejorados de receptor de unión a antígeno |
EP3601346A1 (en) * | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
EP3601345A1 (en) * | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
BR112019024291A2 (pt) * | 2017-06-09 | 2020-07-28 | Providence Health & Services-Oregon | utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer |
CA3071540A1 (en) * | 2017-07-31 | 2019-02-07 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
EP3665197A2 (en) * | 2017-08-11 | 2020-06-17 | H. Hoffnabb-La Roche Ag | Anti-cd8 antibodies and uses thereof |
WO2019175806A1 (en) * | 2018-03-13 | 2019-09-19 | Vascular Biogenics Ltd. | Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules |
GB201815045D0 (en) * | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
CN113039271A (zh) * | 2018-10-02 | 2021-06-25 | 田边三菱制药株式会社 | 靶向黏结蛋白聚糖-1和成纤维细胞生长因子受体的双特异性结合剂 |
WO2021009383A1 (en) * | 2019-07-18 | 2021-01-21 | Lindis Blood Care Gmbh | Removal of tumor cells from intraoperative autologous blood salvage by using a trifunctional antibody |
EP4210735A1 (en) | 2020-09-10 | 2023-07-19 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 antibodies and methods of use thereof |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN112480266B (zh) * | 2020-12-04 | 2021-07-06 | 广州熙帝生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体脐血有核细胞及应用 |
WO2023102119A1 (en) * | 2021-12-01 | 2023-06-08 | The Brigham And Women's Hospital, Inc. | Multispecific t cell engager polypeptides in combination with t cells for cancer therapy |
CN114316060B (zh) * | 2021-12-15 | 2023-06-13 | 北京市肿瘤防治研究所 | 抗人cd19与cd206双特异性抗体及其制备方法和应用 |
CN114716558B (zh) * | 2022-04-12 | 2023-05-05 | 骏蓦(北京)生物科技有限公司 | 一种双特异性抗体及其治疗癌症的应用 |
CN117624375A (zh) * | 2022-08-30 | 2024-03-01 | 北京卡替医疗技术有限公司 | 增强受体、表达增强受体的免疫细胞及其用途 |
WO2024138144A1 (en) * | 2022-12-22 | 2024-06-27 | The Medical College Of Wisconsin, Inc. | Compositions that target cd138 and cd3 and methods of making and using the same |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
EP1348715A3 (en) * | 1998-04-21 | 2003-11-19 | Micromet AG | CD19xCD3 specific polypeptides and uses thereof |
EP1115427B1 (de) * | 1998-09-25 | 2003-12-03 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
DE10043437A1 (de) * | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | T細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
CA2625440C (en) * | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
EP2318434A1 (en) | 2008-07-31 | 2011-05-11 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Her2/neu specific t cell receptors |
EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
PL2417156T3 (pl) | 2009-04-07 | 2015-07-31 | Roche Glycart Ag | Trójwartościowe, bispecyficzne przeciwciała |
EP2241576A1 (en) * | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells |
EP3505636A1 (en) | 2009-04-27 | 2019-07-03 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
AU2010252284A1 (en) | 2009-05-27 | 2011-11-17 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US10633451B2 (en) * | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
BR112014026990A2 (pt) * | 2012-05-24 | 2017-07-11 | Hoffmann La Roche | anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia. |
MX2018015414A (es) * | 2016-06-30 | 2019-08-01 | Hoffmann La Roche | Terapia de célula t adoptiva mejorada. |
-
2013
- 2013-01-24 US US14/376,364 patent/US10633451B2/en active Active
- 2013-01-24 BR BR112014019116-6A patent/BR112014019116B1/pt active IP Right Grant
- 2013-01-24 EP EP13705405.2A patent/EP2809682B1/en active Active
- 2013-01-24 JP JP2014555152A patent/JP6363021B2/ja active Active
- 2013-01-24 CA CA2861031A patent/CA2861031C/en active Active
- 2013-01-24 WO PCT/EP2013/051351 patent/WO2013113615A1/en active Application Filing
- 2013-01-24 MX MX2014008963A patent/MX366965B/es active IP Right Grant
- 2013-01-24 CN CN201380016362.3A patent/CN104379601B/zh active Active
- 2013-01-24 KR KR1020147024588A patent/KR102091297B1/ko active IP Right Grant
- 2013-01-24 RU RU2014133703A patent/RU2693264C2/ru active
-
2015
- 2015-08-11 HK HK15107740.1A patent/HK1207094A1/xx unknown
-
2018
- 2018-02-22 JP JP2018029507A patent/JP6700325B2/ja active Active
-
2020
- 2020-04-02 US US16/838,979 patent/US11732052B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112014019116B1 (pt) | 2024-01-23 |
US10633451B2 (en) | 2020-04-28 |
RU2014133703A (ru) | 2016-04-10 |
CA2861031C (en) | 2022-10-25 |
RU2693264C2 (ru) | 2019-07-01 |
MX2014008963A (es) | 2015-01-16 |
JP2018110586A (ja) | 2018-07-19 |
JP2015506954A (ja) | 2015-03-05 |
KR102091297B1 (ko) | 2020-03-20 |
US20200317806A1 (en) | 2020-10-08 |
JP6363021B2 (ja) | 2018-07-25 |
BR112014019116A2 (pt) | 2018-10-09 |
CN104379601A (zh) | 2015-02-25 |
KR20140127845A (ko) | 2014-11-04 |
MX366965B (es) | 2019-07-31 |
CA2861031A1 (en) | 2013-08-08 |
US20150010567A1 (en) | 2015-01-08 |
EP2809682A1 (en) | 2014-12-10 |
US11732052B2 (en) | 2023-08-22 |
WO2013113615A1 (en) | 2013-08-08 |
HK1207094A1 (en) | 2016-01-22 |
EP2809682B1 (en) | 2020-04-08 |
CN104379601B (zh) | 2021-04-09 |
JP6700325B2 (ja) | 2020-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014019116A8 (pt) | Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo | |
AR125268A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
BR112013020338A2 (pt) | proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
BR112014022932A2 (pt) | molécula de ligação, seu uso e seu método de produção, molécula de ácido nucleico, vetor, célula hospedeira, e composição | |
BR112013031892A2 (pt) | anticorpos anti-psgl-1 e seu uso | |
BR112018077375A2 (pt) | kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente | |
BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
ECSP14004893A (es) | Moléculas de unión para bcma y cd3 | |
BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
CO6351751A2 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos | |
BR112014007382A2 (pt) | anticorpos anti-erbb3 e seus usos | |
AR073775A1 (es) | Anticuerpos biespecificos anti-vegf/anti- ang -2 | |
BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
AR095374A1 (es) | Moléculas de unión para bcma y cd3 | |
BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
BR112015005380A2 (pt) | anticorpos anti-cd3, moléculas biespecíficas de ligação ao antígeno que se ligam à cd3 e cd20, e usos dos mesmos | |
BR112014010591A2 (pt) | proteína de ligação ao antígeno e seu uso como produto de direcionamento para o tratamento de câncer | |
BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
BR112013031262A2 (pt) | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". | |
BR112016013493A2 (pt) | molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo | |
BR122020002402B8 (pt) | Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma | |
BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/01/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |